MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ORIC had -$9,738K decrease in cash & cash equivalents over the period. -$88,972K in free cash flow.

Cash Flow Overview

Change in Cash
-$9,738K
Free Cash flow
-$88,972K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-98,963 -
Depreciation
900 -
Stock-based compensation expense
18,759 -
Accretion of discount on investments, net
2,060 -
Prepaid expenses and other assets
325 -
Accounts payable and accrued other liabilities
-6,798 -
Net cash used in operating activities
-88,487 -
Acquisitions of property and equipment
485 -
Purchases of investments
354,530 -
Maturities of investments
190,000 -
Net cash used in investing activities
-165,015 -
Proceeds from issuance of common stock and pre-funded warrants
244,369 -
Issuance costs associated with financings
2,397 -
Proceeds from issuance of common stock under espp
757 -
Proceeds from stock option exercises
1,035 -
Net cash provided by financing activities
243,764 -
Restricted cash and cash equivalents
-491
Net (decrease) increase in cash, cash equivalents and restricted cash
-9,738 -
Cash and cash equivalents, at carrying value, ending balance
-75,864
Cash and cash equivalents at beginning of period
59,897 -
Cash and cash equivalents at end of period
50,159 76,355
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Oric Pharmaceuticals, Inc. (ORIC)

Oric Pharmaceuticals, Inc. (ORIC)